维普期刊资源整合服务平台（V6.5）

122篇 您的检索式：作者名="Nicolantonio"

选中清除导出查看参考文献查看引证文献引用追踪共7页首页上一页第1页下一页末页 /7 跳转

	题名	作者	年代	出处	被引量
1	Morphology, flight performance, and water crossing tendencies of Afro-Palearctic raptors during migration显示文摘	Nicolantonio AGOSTINI Michele PANUCCIO Cristian PASQUARETTA	2015	Current Zoology2015，61，6：	4
2	Wildtype BRAF is required for response to panitumumab or eetuximah in metastatic colorectal cancer 显示文摘	Di Nicolantonio F Martini M Molinarl F	2008	J Clin Oncol2008，26，35：	1
3	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer显示文摘	Di Nicolantonio F Martini M Molinari F	2008	J Clin Oneol2008，26，35：	1
4	Wild-type BRAF is required for responseto panitumurnab or cetuximab in metastatic colorectal cancer显示文摘	DI NICOLANTONIO F MARTINI M MOLINARI F	2008	J Clin Oncol2008，26，35：	1
5	Multi -De- terminants Analysis of Molecular Alterations for Predicting Clinical Benefit to EGFR - Targeted Monoclonal Antibodies in Colorectal Cancer显示文摘	Sat'tore -Bianchi A Di Nicolantonio F Nichelatti M	2009	PLoS ONE2009，4，10：	1
6	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer显示文摘	Di Nicolantonio F Martini M Molinari F	2008	J Clin Oncol2008，26，35：	1
7	Ex vivo reversal chemo resistance by tarquidar(XR9576)显示文摘	Di Nicolantonio F Knight L A Glaysher S	2004	Anticancer Drugs2004，15，9：	1
8	Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer显示文摘	Siena S Sartore-Bianchi A Di Nicolantonio F	2009	J Natl Cancer lnst2009，101，19：	1
9	Ex vivo reversal chemo - resistance by tarquidar ( XR9576 ) 显示文摘	Di Nicolantonio F Knight LA Glaysher S	2004	Anticancer Drugs2004，15，9：	1
10	Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer 显示文摘	Di Nicolantonio F Martini M Molinari F	2008	J Clin Oncol2008，26，35：	1
11	Chemo- sensitization of Solid Tumors by Modulation of Resistance Mechanisms 显示文摘	Cree I A Knight L Di Nicolantonio F	2002	Curr Opin Investing Drugs2002，3，4：	1
12	Wildtype BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer显示文摘	DI NICOLANTONIO F MARTINI M MOLINARI F	2008	J Clin Oncol2008，26，35：	1
13	Liquid biopsy:monitoring cancer-genetics in the blood显示文摘	Crowley E Di Nicolantonio F Loupakis F	2013	Nat Rev Clin Oncol2013，10，8：	1
14	Wild-type BRAF is required for response to panitumumab orcetuximab in metastatic colorectal cancer显示文摘	Di Nicolantonio F Martini M Molinari F	2008	J Clin Oncol2008，26，35：	1
15	Liquid biopsy: monitoring cancer-genetics in the blood 显示文摘	Crowley E Di Nicolantonio F Loupakis F	2013	Nat Rev Clin Oncol2013，10，8：	1
16	Aerosol remote sensing over land: A comparison of satellite retrievals using different algorithms and instruments显示文摘	A.A. Kokhanovsky F.-M. Breon A. Cacciari E. Carboni D. Diner W. Di Nicolantonio R.G. Grainger W.M.F. Grey R. H?ller K.-H. Lee Z. Li P.R.J. North A.M. Sayer G.E. Thomas W. von Hoyningen-Huene	2007	Atmospheric Research2007，，3：	1
17	The ex vivo characterization of XR5944 (MLN944) against a panel of human clinical tumor samples显示文摘	Di Nicolantonio F Knight LA Whitehouse PA	2004	Mol Cancer Ther2004，3，12：	1
18	Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus显示文摘	Di Nicolantonio Federica Arena Sabrina Tabernero Josep Grosso Stefano Molinari Francesca Macarulla Teresa Russo Mariangela Cancelliere Carlotta Zecchin Davide Mazzucchelli Luca Sasazuki Takehiko Shirasawa Senji Geuna Massimo Frattini Milo Ba	2010	Journal of Clinical Investigation2010，，8：	1
19	Cancer celladaptation to chemotherapy显示文摘	Di Nicolantonio F Mercer S J Knight L A	2005	BMC Cancer2005，5，1：	1
20	Liquidbiopsy: monitoring cancer-genetics in the blood 显示文摘	Crowley E Di Nicolantonio F Loupakis F	2013	NatRev Clin Oncol2013，10，：	1

返回顶部每页显示：

共7页首页上一页第1页下一页末页 /7 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示